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The homocysteine hypothesis states that circulating
homocysteine is a vascular toxin in concentrations that occur
in the general population and in renal failure. This hypothesis
is currently being tested in the Kidney and End State Renal
Disease Study (HOST), but data have emerged since the HOST
began that suggest its results will be inconclusive. The crucial
treatment component in the HOST is folic acid, but its effect
is likely to be lost because the American food supply is now
fortified with folic acid. A second concern is that the very
high doses of folic acid and pyridoxine being used in the
HOST may confound the results. Finally, confounding due to
‘reverse epidemiology’ was not considered when the HOST
was designed. Parenteral vitamin B12 is a highly promising
therapy for homocysteine reduction in end-stage renal
disease that merits careful investigation. Clinical trials using it
to test the homocysteine hypothesis will avoid the problems
inherent in the HOST.
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There is little doubt that in sufficiently high concentrations
homocysteine is a vascular toxin. In untreated homocysti-
nuria, plasma total homocysteine (tHcy) concentrations
range between 100 and 400 mmol/l; unless these are lowered
by vitamin therapy, patients die at a young age from venous
thromboembolism and malignant arterial disease.1–4 Hyper-
homocysteinemia causes arterial disease in experimental
animals 5–8 by a variety of plausible mechanisms.3,9–12 The
important question – the ‘homocysteine hypothesis’ – is
whether homocysteine is toxic in concentrations that occur
in the general population (5–15 mmol/l) or in advanced and
end-stage renal disease (ESRD) (15–50 mmol/l), and whether
lowering these concentrations will slow the progression of
cardiovascular disease.13
Most epidemiologic studies have shown a strong and
graded association between the risk of cardiovascular events
and plasma tHcy concentrations as low as 10 mmol/l.1,14–16
Some inconsistencies that have been reported in this
relationship may be reconciled if other vascular risk factors
are required to be present for mild hyperhomocysteinemia to
be toxic.17–19 This interaction would also account for the
effectiveness of vitamin therapy in preventing vascular
complications in vitamin-responsive homocystinuria despite
residual mild hyperhomocysteinemia.4
Ultimately, proof of the homocysteine hypothesis will
require convincing results from hard end point randomized
clinical trials.20 In a prospective randomized clinical trial in
Switzerland, 6 months of daily therapy with 1 mg folic acid,
0.4 mg vitamin B12, and 10 mg pyridoxine lowered the
average plasma tHcy concentration from 11.4 to 7.5 mmol/l
and substantially reduced the need for revascularization in
coronary angioplasty patients, especially those treated by
balloon angioplasty.21–23 In a different study from the
Netherlands, daily therapy with 1.2 mg folic acid, 60 mg
vitamin B12, and 48 mg pyridoxine paradoxically increased
the incidence of coronary restenosis in patients treated by
intracoronary stenting, despite lowering the average plasma
tHcy concentration from 12.2 to 9.0 mmol/l.24
In the Vitamin Intervention for Stroke Prevention (VISP)
study, 3680 Americans and Canadians with a recent stroke
were randomized to a daily regimen of 2.5 mg folic acid,
0.4 mg vitamin B12, and 25 mg pyridoxine or control
tablets.25 This treatment lowered the average plasma tHcy
concentration only slightly from 13.4 to 11 mmol/l, and had
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no detectable effect on vascular outcomes during the 2 year
follow-up period. The VISP study began just as grain
products in the American and Canadian diet were fortified
with synthetic folic acid. This intervention lowered plasma
tHcy concentrations in the general population,26 diminishing
the effect of folic acid in the therapeutic arm of the VISP and
other studies.27,28 The diet is not fortified with folic acid in
Europe, and in a clinical trial recently completed there 50
patients with increased carotid intima-media thickness were
randomized to the same vitamin regimen as in the VISP
study.29 Vitamin therapy lowered the average plasma tHcy
concentration from 10.5 to 6.6 mmol/l, more than twice as
much as in the VISP study, and was associated with a
significantly lower carotid intima-media thickness.29
Chronic renal failure and ESRD are important conditions
in which to test the homocysteine hypothesis.30 If the
homocysteine hypothesis were to be confirmed in this
population, it would increase the likelihood that homo-
cysteine lowering at an early stage of renal disease could slow
its progression.31 The Homocysteinemia in Kidney and End
State Renal Disease Study (HOST) is a US Veterans
Administration–industry funded clinical trial initiated in
2001 to determine the effect of 4 years of a daily regimen
of 40 mg folic acid, 100 mg pyridoxine, and 2 mg of vitamin
B12 on vascular outcomes in persons with advanced chronic
renal failure and ESRD (http://clinicaltrials.gov/ct/show/
NCT00032435). Since 2001 data have emerged that strongly
suggest the HOST will be inconclusive.
Folic acid is the key therapeutic component in the HOST,
but, as demonstrated by the VISP study, the homocysteine-
lowering effect of folic acid is likely to be lost because the
American food supply is now fortified. The 40 mg dose of
folic acid being used in HOST is no more effective than 1 mg/
day at reducing plasma tHcy concentrations32–35 and may
create confusion, since high-dose folic acid could have a
therapeutic benefit independent of plasma homocysteine
lowering.36 Thus, even a positive outcome of the HOST
would leave the homocysteine hypothesis untested.
A second problem is the use of pyridoxine in dose more
than 60 times the recommended intake of 1.5 mg/day. The
only noteworthy design difference between the Swiss and
Netherlands angioplasty trials is the extremely high pyridox-
ine dose used in the Netherlands study, in which active
treatment led to an adverse outcome.24 This result raises the
disturbing possibility that very-high dose pyridoxine could
be toxic in some situations. Pyridoxine is neurotoxic in very
high doses.3 The active form of the vitamin, pyridoxal 50-
phosphate, has a variety of biochemical actions, some of
which are beneficial in short-term clinical studies;37,38 but
any biologically active molecule could have potentially
harmful long-term effects in very high doses, particularly in
the absence of a mitigating benefit such as homocysteine
lowering. The extremely high folic acid and pyridoxine doses
being used in the HOST are biochemically unjustified. Both
vitamins reduce plasma tHcy concentrations by eliminating a
deficiency state, and there is no good evidence that doses
higher than necessary to eliminate deficiency cause additional
plasma tHcy lowering, except in homocystinuria. High-flux
dialyzers remove pyridoxal-50-phosphate efficiently, but daily
pyridoxine doses of 10, or at most 20 mg/day appear to
compensate adequately for it.39,40
Third, any test of the homocysteine hypothesis must take
into account the problem of ‘reverse epidemiology.’ Some
ESRD patients have low plasma tHcy concentrations that are
related to inflammatory states, malnutrition, and hypoalbu-
minemia, all of which are associated with a poor clinical
outcome.41–43 Approximately 70% of plasma tHcy circulates
bound to albumin, so hypoalbuminemia lowers plasma tHcy
concentrations without necessarily lowering concentrations
of the metabolically active species, reduced homocysteine.43
Patients with plasma tHcy concentration as low as 15 mmol/l
are enrolled in the HOST. Reverse epidemiology could well
apply to these patients. Another concern with enrolling such
patients is that their plasma tHcy concentrations are most
unlikely to decrease with treatment; their inclusion will
merely dilute the results.44
An alternative and highly potent treatment is now
available to reduce plasma tHcy in ESRD, namely, parenteral
vitamin B12. Observational data
45,46 motivated us to carry
out a randomized clinical trial comparing the effect of
standard high-dose oral folic acid, pyridoxine, and vitamin
B12 with the same regimen to which 1 mg hydroxocobalamin
was administered parenterally after dialysis once per week.
This addition lowered plasma tHcy concentrations by an
average of 32%.47 Almost simultaneously, a controlled trial by
Koyama et al.48 demonstrated an even greater, 50% reduction
in plasma tHcy by the addition of 0.5 mg intravenous
methylcobalamin after every dialysis to a high-dose folic acid-
pyridoxine regimen. We have now published two additional
confirmatory controlled trials in different hemodialysis
patient populations,49,50 the most recent of which showed
that 1 mg/day folic acid is sufficient for folate repletion, and
that intravenous cyanocobalamin and hydroxocobalamin are
equipotent even though they increase serum cobalamin levels
differently.50 Three other centers have now reported that a
vitamin combination which includes parenteral vitamin B12
lowers plasma tHcy concentrations of hemodialysis patients
to normal or nearly normal.51–53 Since massive daily oral
vitamin therapy (including oral vitamin B12) lowers ESRD
plasma tHcy by no more than one-third,54–58 these reports
represent further confirmation that parenteral vitamin B12 is
the critical component responsible for normalizing plasma
tHcy concentrations in folate- and vitamin B12-replete ESRD
patients.
The cause of renal failure-associated hyperhomocysteine-
mia continues to be debated.59,60 Reduced renal mass likely
plays a role since the kidney contains enzymes for
metabolizing homocysteine and cysteine, and the concentra-
tions of both amino acids are increased in renal failure.45,61
The clinical reports now available from several centers
provide strong inferential evidence that uremia induces
hyperhomocysteinemia by inhibiting methionine synthase,
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the cobalamin-dependent enzyme that catalyzes homocys-
teine remethylation to methionine. Pharmacologic concen-
trations of cobalamin are known to increase methionine
synthase activity many-fold via a post-translational mechan-
ism.62 Cobalamin must be administered parenterally because,
unlike folic acid or pyridoxine, its oral bioavailability is too
limited to raise tissue concentrations to the required
pharmacologic level.46 This novel understanding of cobala-
min metabolism in uremia is in line with an earlier
suggestion by van Guldener et al.,63 who concluded from a
clinical tracer study that homocysteine remethylation is
impaired in hemodialysis patients.
It is appropriate to confirm the homocysteine-lowering
effect of parenteral cobalamin in ESRD in additional centers
(preferably the potent regimen of 0.5 mg intravenously after
every dialysis used by Koyama et al.48) without waiting for
the results of the HOST. Cyanocobalamin, an inexpensive
and widely available form of the vitamin used in North
America, is probably equipotent to the methylcobalamin
used by Koyama et al.48 There are major advantages to testing
a regimen such as 1 mg oral folic acid, 10 or 20 mg oral
pyridoxine, and 0.5 mg intravenous cobalamin after every
dialysis. This regimen will avoid potentially serious con-
founding due to high-dose folic acid and pyridoxine as used
in the HOST. The lowering of plasma tHcy can be anticipated
to be from approximately 25 to 12 mmol/l, which is
sufficiently great to permit a study that enrolls many fewer
patients than in the HOST. To avoid confounding due to
reverse epidemiology, patients with hypoalbuminemia, mal-
nutrition, or a plasma tHcy less than B20 mmol/l should be
excluded from studies of the homocysteine hypothesis in
ESRD.
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